OBJECTIVES Ablation along the posterior wall of left atrium can result in atrioesophageal fistula due to thermal injury to the esophagus. The purpose of our study was to investigate whether contrast visualization of the esophagus reduces collateral injury during atrial fibrillation (AF) ablation.
METHODS Active-fixation leads were used in 85 consecutive sick sinus syndrome or high-grade atrioventricular block patients with (Group 1, n¼22) or without (Group 2, n¼63) amputation of RAA underwent implantation of dual-chamber pacemakers. X-ray, threshold, sensing, impedance, average implantation exposure time and lead-related complications were evaluated at implantation (D0), and at 1, 3, 6, 12, 24 , and 36 months.
RESULTS All leads were successfully implanted. Over long-term follow-up, all leads remained stable as evidenced by X-ray. Initial sensing of both groups were equal and stable in both groups. Impedance declined slightly (P>0.05) from D0 to M1 and remained stable thereafter. Threshold of atrial pacing lead decreased significantly during the first 3 months and remained stable thereafter while the threshold of ventricular pacing lead remained stable throughout the whole study, with neither of them showing significant difference between groups. No lead-related complications were found.
CONCLUSIONS Active-fixation atrial pacing leads can be successfully fixed to the bottom of the residual appendage in patients undergone amputation of RAA with overall good and stable long-term parameters. OBJECTIVES The prolongation of QT interval is associated with cardiovascular mortality and morbidity. QT prolongation is common in patients with sickle cell disease and it is reported that a lower hemoglobin level correlates with a longer QT interval in these patients. Such correlation, however, has not been determined in patients with other types of hematologic disorders. This study aims to investigate whether there is an association between reduced hemoglobin and QT interval in patients with anemia caused by disorders other than sickle cell disease.
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METHODS ECGs of patients with hemoglobin (Hgb) <10 g/dl enrolled from our Hematology Department were evaluated for the presence of QT prolongation using Bazett's formula for heart rate corrected QTc. In subjects with QRS duration >120 ms, JT index (JTI¼JT(HRþ100)/518) was applied to estimate their repolarization time. It is reported that JTI > 112 is an indication of delayed ventricular repolarization. Among study subjects (Hgb 8.0AE1.6 g/dl, range 1.9-9.9 g/dl), moderate anemia (Hgb 6-9 g/dl) accounted for 56% and severe anemia (Hgb <6 g/dl) for 12%. Anemia was related to leukemia in 40% (121/300), lymphoma in 28%, myelodysplastic syndrome in 9%, multiple myeloma in 8%, aplastic anemia in 4%, and the remainder with other types of hematologic disorders. None of the patients had left ventricular hypertrophy, electrolyte abnormalities, or were receiving QT-prolonging drugs.
RESULTS The average QTc in 300 patients with hematologic disorders was 414 AE 23 ms. There were 21 patients with a QTc >440 ms. Nevertheless, 33% (7/21) of them had a prolonged depolarization time (QRS duration !120 ms) including complete left (4), right bundle branch blocks (1) and right ventricular pacing (2), respectively. Their JT index were all <112 ms, suggesting the repolarization time was normal. Therefore, only 5% (14/300) of all anemic patients had a borderline to moderate QTc prolongation (461AE 13 ms, range: 441-479 ms) and none of them experienced syncope, cardiac arrest, or sudden death. Linear regression analysis showed no significant correlation between reduced hemoglobin level and QT prolongation (P¼0.587). To determine whether the severity of anemia affects QTc interval, study subjects were then divided into three groups separated by Hgb levels. The result of ANOVA showed no statistical significance between the lengths of QTc in the 3 groups (P¼0.656).
CONCLUSIONS In anemic patients without left ventricular hypertrophy, electrolyte imbalances, use of QT-prolonging drugs, or any other identifiable causes of ALQTS, the QT interval is normal in most cases, and there is no significant correlation between hemoglobin level and QT interval. METHODS The cMSCs were transfected with pLentis-mShox2-RFP or pLentis-RFP. After EPCS induction, these cells were designed into four groups: the RFP transfected cMSCs (Group A as control), the RFP transfected cMSCs induced by EPCS (Group B), the mShox2-RFP transfected cMSCs (Group C), and the mShox2-RFP transfected cMSCs induced by EPCS (Group D). We examined the kinetic characteristics of generated inward current by patch-clamp. We then evaluated Nkx2.5, Tbx3, HCN4, Cx43 and Cx45 expression using qRT-PCR and Western blotting.
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RESULTS
The time-and voltage-dependent inward current recorded in group C was confirmed as the I f current. After EPCS induction, the detection rate of this I f current was increased (Group D), the current amplitude and density were extend. However, there were no I f current in groups A and B. Compared with the control group(Group A), Tbx3, HCN4, Cx45 were significantly up-regulated but Nkx2.5, Cx43 were down-regulated in groups C and D. Whereas Nkx2.5 and Cx43 were up-regulated in group B.
CONCLUSIONS Our results suggest that EPCS can promote the differentiation of mShox2 genetically modified cMSCs into pacemakerlike cells, generating If current.
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Successful Treatment of a LQT8 Case with Mexiletine: 4 years of experience METHODS Mexiletine (12.5 mg/kg per day) was initiated when the proband's 12-lead ECG revealed QTc of 600 ms, 2:1 AVB and TWA. 12-lead ECGs and Holter monitoring were obtained once per month during the first year. Afterwards, Holter monitoring was performed once in every 3-4 months. The QT interval was measured on lead II or V5. Heart rate-corrected QT (QTc) was calculated using Bazett formula (QT/ORR). The QT/RR slope was calculated based on the Holter results.
RESULTS During the first two years of treatment of mexiletine at a maintenance dose of 150 to 200 mg daily, her ECGs and the Holter monitoring revealed no 2:1 AVB and TWA, blunted QT/RR relationship and QTc in a range from 500 to 560 ms. During this period, the patient successfully underwent two syndactyly repair surgeries although the anesthesiologist reported occurrence of one episode of non-sustained polymorphic ventricular tachycardia during her second operation. In the past one year, this patient had two episodes of syncope or "seizure" activities. In one longer episode, she happened to wear a Holter which did not reveal any ventricular arrhythmias. Although they were not correlated to her syncope, 2:1 AVB and TWA reappeared. Her mexiletine dose was then adjusted to 250 mg daily. Dose increase in mexiletine abolished 2:1 AVB and TWA.
CONCLUSIONS Our experiences suggests that inhibition of I Na, L by mexiletineis a promising pharmacotherapeutic approach in reduction of arrhythmic risks in TS. However, mexiletine appears to lose its efficacy slowly with time.
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Meta-analysis of the HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation OBJECTIVES Three validated HAS-BLED, HEMORR 2 HAGES and ATRIA bleeding scores, or even the CHADS 2 and CHA 2 DS 2 -VASc stroke scores, could be used to evaluate atrial fibrillation(AF) patients' major bleeding risk. These scores have been validated in the various independent studies. We therefore compared the diagnostic accuracy of the HAS-BLED score to that of other risk scores in anticoagulated patients with AF.
METHODS We systematically searched the Cochrane Library, Medline, PubMed and Embase databases for studies of the comparative diagnostic performance between the HAS-BLED score and any of the HEMORR 2 HAGES, ATRIA, CHADS 2 or CHA 2 DS 2 -VASc scores. Data were extracted from applicable studies, and then analyzed using statistical methods such as the discrimination, calibration, net reclassification improvement(NRI) and integrated discrimination improvement(IDI) analysis. The primary endpoints of AF patients were also defined dichotomously and compared between scores <3 and !3 for the HAS-BLED score.
RESULTS 11 studies were identified for meta-analysis. We performed the discrimination analysis by means of C-statistic with 95% confidence interval(CI). The pooled C-statistics respectively are 0.65(0.61-0.69) for HAS-BLED, 0.63(0.61-0.66) for HEMORR 2 HAGES, 0.63(0.56-0.72) for ATRIA, 0.55(0.49-0.61) for CHADS 2 and 0.56(0.53-0.59) for CHA 2 DS 2 -VASc. The HAS-BLED score demonstrates no significant differences of C-statistic for major bleeding risk prediction when compared to the ATRIA or HEMORR 2 HAGES bleeding scores, but gets the opposite results when compared to the CHADS 2 or CHA 2 DS 2 -VASc stroke scores. These results are further supported by the significant positive NRI and IDI values. Calibration analysis indicates the HAS-BLED score over-predicts the risk of bleeding in the low (RR¼1.16,95%CI 0.63-2.13;P¼0.64) risk stratification, but under-predicts the risk of bleeding in the moderate (RR¼0.66,95%CI 0.51-0.86;P¼0.002) and high (RR¼0.88,95%CI 0.70-1.10; P¼0.27) risk stratifications. There are no significant differences between the predicted and the observed major bleeding events in the low and high risk stratifications. With regard to the occurrence of major bleeding events individually, patients with HAS-BLED scores !3 have a greater risk of major bleeding(RR¼2.97,95%CI, 2.32-3.80;P<0.00001) than patients with HAS-BLED scores <3. A chi-squared test for trend shows an increasing trend in the occurrence of major bleeding events across three risk stratifications according to the HAS-BLED score(c 2 ¼108.57, P trend <0.001).
CONCLUSIONS The HAS-BLED score not only performs better than the HEMORR 2 HAGES and ATRIA bleeding scores, but also is superior to the CHADS 2 and CHA 2 DS 2 -VASc stroke scores for bleeding prediction. The HAS-BLED score should be the optimal choice to assess major bleeding risk in clinical practice. OBJECTIVES An elevated left atrial pressure (LAP), a sign of atrial structural remodeling, has been reported as a mechanism of atrial fibrillation (AF). However, the effect of LAP on the recurrence after AF catheter ablation has not been well elucidated. We aimed to address the predictive value of LAP and observe the influence for prognosis.
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METHODS 150 patients of AF who underwent a first-time catheter ablation in our hospital were enrolled in the present study. Including paroxysmal AF (n¼66) and persistent AF (n¼84). All patients underwent transseptal puncture during procedure. LAP were measured during sinus rhythm. According to the values of LAP, the patients were divided into each two groups, high LAP ofparoxysmal AF group (HP-PAF) and low LAP of paroxysmal AF group (LP-PAF), high LAP of persistent AF group (HP-PeAF) and low LAP of persistent AF group (LP-PeAF). The relationship between LAP and clinical variables were analyzed. Recurrence rates of the each two groups were evaluated through follow-up. Cox-regression analysis was implemented to find out the independent determinants of AF/AT recurrence after FRCA.
RESULTS (1) 150 AF patients were successfully followed up in the study. Following up (10.2AE4.9) months, 17 patients (51.5%) in HP-PAF group and 29 patients (87.9%) in LP-PAF group maintained sinus after RFCA (P<0.01). 15 patients (33.3%) in HP-PeAF group and 33 patients (84.6%) in LP-PeAF group maintained sinus rhythm after RFCA (P<0.01).
(2) For paroxysmal AF, LVEF (linear regression coefficient B¼-0.761, P¼0.002) was a good noninvasive parameter independently associated with LAP. For persistent AF, duration of AF(B¼0.826, P<0.001), CHADS 2 -VASc score(B¼2.327, P<0.001), LAVI(B¼0.424, P<0.001 ), IVS(B¼2.847, P<0.001), E/e' (B¼-3.330, P<0.001), LVEF(B¼-0.651, P<0.001) were good noninvasive parameters independently associated with LAP-PeAF.
(3) For paroxysmal AF, Cox-regression analysis revealed that LAP (OR 1.27; 95%CI: 1.11-1.45; P<0.01) was the independent predictor of AF/AT recurrence after FRCA. The area under ROC curve of LAP was 0.626. The cutoff point was 16.75mmHg (sensitivity 76.2%, specificity 82.2%). For persistent AF, LAP (OR 1.56;95%CI: 1.11-1.82; P¼0.019) was also the independent predictor of AF/AT recurrence after FRCA. The area under ROC curve of LAP was 0.836. The cutoff points were 17.3mmHg (sensitivity 83.3%, specificity 88.9%). In addition, duration of AF, the antero-posterioratrial diameter of left atrium and LVEF were also the independent predictors of AF/AT recurrence after FRCA. And the predictive value of LAP was higher than that of others.
CONCLUSIONS (1) Elevated LAP was closely associated with anatomical remodeling of the left atrium and was an independent predictor for clinical recurrence after AF ablation.
(2) For paroxysmal AF, LVEF was a good noninvasive parameter independently associated with LAP. For persistent AF, duration of AF, CHADS 2 -VASc score, LAVI, IVS E/e', LVEF were good noninvasive parameters independently associated with LAP-PeAF.
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Cuijun Hao, Xiuchun Yang, Jingchao Lu, Fan Liu The Second Hospital of Hebei Medical University OBJECTIVES We will analyze the coronary venous system anatomy through coronary vein direct enhancement and inverse development. The conclusion will be used to confirm electrophysiological examination, radio frequency ablation, implantation of a LV lead and so on.
